Cargando…

Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors

Detalles Bibliográficos
Autores principales:	Ma, Chunlong, Wang, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923551/ https://www.ncbi.nlm.nih.gov/pubmed/33568498 http://dx.doi.org/10.1073/pnas.2024420118

Ejemplares similares

Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations
por: Rhee, Soo-Yon, et al.
Publicado: (2022)

Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays
por: Ma, Chunlong, et al.
Publicado: (2022)

Monomorphic ventricular tachycardia due to protease inhibitor intoxication by atazanavir
por: Kim, Byunghyun, et al.
Publicado: (2018)

Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor
por: Tan, Haozhou, et al.
Publicado: (2022)

Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor
por: Tan, Haozhou, et al.
Publicado: (2022)

Potential SARS-CoV-2 main protease inhibitors
por: Banerjee, Riddhidev, et al.
Publicado: (2021)

Developing inhibitors of the SARS-CoV-2 main protease
por: Seitz, Christian, et al.
Publicado: (2022)

Allosteric inhibitors of the main protease of SARS-CoV-2
por: Samrat, Subodh Kumar, et al.
Publicado: (2022)

Is Ritonavir-Boosted Atazanavir a Risk for Cholelithiasis Compared to Other Protease Inhibitors?
por: Hamada, Yohei, et al.
Publicado: (2013)

Montelukast and Telmisartan as Inhibitors of SARS-CoV-2 Omicron Variant
por: Mulgaonkar, Nirmitee, et al.
Publicado: (2023)

Validation and Invalidation of SARS-CoV-2 Papain-like Protease Inhibitors
por: Ma, Chunlong, et al.
Publicado: (2022)

Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors
por: Ma, Chunlong, et al.
Publicado: (2020)

Biochemical screening for SARS-CoV-2 main protease inhibitors
por: Coelho, Camila, et al.
Publicado: (2020)

Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors
por: Huff, Sarah, et al.
Publicado: (2021)

Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease
por: Katagishi, Daiki, et al.
Publicado: (2023)

Potent and biostable inhibitors of the main protease of SARS-CoV-2
por: Tsuji, Kohei, et al.
Publicado: (2022)

Effect of the African Traditional Medicine, Sutherlandia frutescens, on the Bioavailability of the Antiretroviral Protease Inhibitor, Atazanavir
por: Müller, Adrienne C., et al.
Publicado: (2013)

Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2′s main protease
por: Mahdi, Mohamed, et al.
Publicado: (2020)

Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors
por: Ma, Chunlong, et al.
Publicado: (2020)

Computational Prediction of Potential Inhibitors of the Main Protease of SARS-CoV-2
por: Abel, Renata, et al.
Publicado: (2020)

A cyclic peptide inhibitor of the SARS-CoV-2 main protease
por: Kreutzer, Adam G., et al.
Publicado: (2021)

Fragment-based inhibitor design for SARS-CoV2 main protease
por: Andola, Priyanka, et al.
Publicado: (2022)

Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease
por: Kuang, Yi, et al.
Publicado: (2023)

In silico assessment of diterpenes as potential inhibitors of SARS-COV-2 main protease
por: Abdelrady, Yousef A, et al.
Publicado: (2023)

Multicomponent Synthesis of the SARS-CoV-2 Main Protease Inhibitor Nirmatrelvir
por: Preschel, H. Daniel, et al.
Publicado: (2023)

Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332
por: Zhao, Yao, et al.
Publicado: (2021)

Insect protease inhibitors; promising inhibitory compounds against SARS-CoV-2 main protease
por: Hemmati, Seyed Ali, et al.
Publicado: (2022)

Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir
por: Jose, Sophie, et al.
Publicado: (2017)

DFT investigation of atazanavir as potential inhibitor for 2019-nCoV coronavirus M protease
por: Shahab, Siyamak, et al.
Publicado: (2021)

Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir
por: Xia, Zilei, et al.
Publicado: (2021)

Repurposing of renin inhibitors as SARS-COV-2 main protease inhibitors: A computational study
por: Refaey, Rana H., et al.
Publicado: (2021)

Molecular dynamics simulation of docking structures of SARS-CoV-2 main protease and HIV protease inhibitors
por: Cardoso, Wesley B., et al.
Publicado: (2021)

Atazanavir versus lopinavir on Covid-19 infection: A retrospective protease inhibitors comparative study 2020
por: Alikhani, Ahmad, et al.
Publicado: (2022)

Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2
por: Tripathi, Praveen Kumar, et al.
Publicado: (2020)

Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2
por: Ghahremanpour, Mohammad M., et al.
Publicado: (2020)

Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
por: Mengist, Hylemariam Mihiretie, et al.
Publicado: (2021)

2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease
por: Forrestall, Katrina L., et al.
Publicado: (2021)

Design and Evaluation of Bispidine-Based SARS-CoV-2 Main Protease Inhibitors
por: Shcherbakov, Dmitriy, et al.
Publicado: (2021)

Challenges of short substrate analogues as SARS-CoV-2 main protease inhibitors
por: Ullrich, Sven, et al.
Publicado: (2021)

A Genetic Trap in Yeast for Inhibitors of SARS-CoV-2 Main Protease
por: Alalam, Hanna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_va49o01netjrgven0tp9rc2pli